Skip to main content
NEKTAR THERAPEUTICS logo

NEKTAR THERAPEUTICS — Investor Relations & Filings

Ticker · NKTR ISIN · US6402681083 LEI · 5299005I24806IOIYE03 US Manufacturing
Open in API
Filings indexed 1,237 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country US United States of America
Listing US NKTR

About NEKTAR THERAPEUTICS

https://www.nektar.com/

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for autoimmune and inflammatory conditions. The company's research centers on modulating the immune system to resolve imbalances and restore homeostasis. By leveraging its expertise in immune pathways, Nektar aims to develop first-in-class, disease-modifying therapies that address the root causes of immune dysfunction. Its pipeline includes investigational candidates such as rezpegaldesleukin, a therapy designed to stimulate regulatory T cells for the treatment of conditions like severe alopecia areata.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K reporting Item 5.07 "Submission of Matters to a Vote of Security Holders" for Nektar Therapeutics’ Annual Meeting, providing the detailed vote counts for proposals. This is a definitive declaration of voting results from a shareholder meeting, matching the Definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-05 English
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Capital/Financing Update Classification · 80% confidence The document is a Form 8-K current report containing an Equity Distribution Agreement under Item 1.01 (an at-the-market offering of up to $150 million of common stock) and a management change under Item 5.02. The Equity Distribution Agreement is a clear update on the company’s fundraising/financing activities, fitting the “Capital/Financing Update” category (CAP).
2026-05-08 English
ARS
Annual Report
2026-04-24 English
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 21, 2026, reporting the entry into a material definitive agreement related to an underwritten offering of common stock by Nektar Therapeutics. It details the underwriting agreement, the number of shares offered, pricing, and related legal opinions. The document is a current report on a specific event (capital raising through stock offering) rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results but focuses on financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6862 characters) supports it being a substantive filing rather than a brief announcement or certification.
2026-04-23 English
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other disclosures typical of securities offering documents. It is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial results or governance. Instead, it is a capital markets document related to a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2026-04-23 English
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock and pre-funded warrants. It references a registration statement filed with the SEC under Rule 424(b)(5), which is a form used for prospectus supplements in securities offerings. The content includes detailed terms of the offering, underwriting information, risk factors, and legal disclaimers typical of a securities offering document. This type of document is related to capital raising activities and financing updates rather than financial reports, management changes, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a substantive offering document.
2026-04-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.